Metal-Based Drugs

Research Article

Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion

Table 2

Effect of KP1019 on lung metastases formation in mice with MCa mammary carcinoma.


(A)	Primary tumour weight (mg)		Lung metastases
	Day 13	Day 20	Number	Weight (mg)

Controls	1627 286	3068 616	29.2 8.10	18.6 12.1
KP1019 40 mg	1095 592	2537 563	31.9 19.2	11.8 11.8
	(67%)	(83%)	(109%)	(63%)

(B)	Primary tumour weight (mg)		Lung Metastases
	Day 13	Day 20	Number	Weight (mg)

Controls	1004 174	2415 439	17.5 10.0	5.70 6.90
KP1019 80 mg	527 136.66	1764 37	19.9 23.2#	3.43 5.83#
	(52%)	(73%)	(114%)	(60%)

Groups of 9 (experiment A) or 11 (experiment B) CBA mice, inoculated I.M. with MCa tumour cells on day 0 were treated I.P. with KP1019 at 40 mg/kg/day from day 6 to day 11 (A) and 80 mg/kg/day on days 7, 9, and 11 (B) after tumour implant. Data in parentheses are expressed as the percentage of the treated versus controls (T/C%), Lung metastases were determined on day 20 after tumour implant, : versus controls, ANOVA, and Tukey-Kramer post test, #: excluded the animals free of macroscopically detectable metastasis (2/11).